NR4A1 and breast cancer: Though adjuvant endocrine therapy (AET) has proven efficacy in treating hormone receptor–positive (HR-positive) breast cancer, patient adherence to AET and continuation of treatment as recommended by guidelines remain suboptimal, especially for low-income patients.